VanEck Pharmaceutical ETF News

The VanEck Pharmaceutical ETF (PPH) was launched on 12/20/2011, and is a passively managed exchange traded fund designed to offer broad exposure to the Healthcare - Pharma segment of the equity market

Digging into the first quarter's earnings season allows us to uncover the winning themes of the period as captured by ETFs.

Many industry bigwigs reported solid results, with some beating on earnings or revenues or both.

Eli Lilly and Company (LLY) raised its outlook for 2024 on rapidly climbing sales of the new obesity drug Zepbound and its counterpart for diabetes, Mounjaro.

Weight-loss drugs, including Ozempic, are reshaping consumer habits. Additionally, they are providing some ballast to what's recently been a sluggish healthcare investment thesis.

VanEck Pharmaceutical ETF is a popular option for investors looking for exposure to leading pharmaceutical companies. The ETF has been in an uptrend since late last year and is currently trading at a

Johnson & Johnson (JNJ) continued with its long streak of earnings beat but lagged revenue estimates.

People are interested in ETFs for weight loss because of Oprah's TV show “Shame, Blame, and the Weight Loss Revolution,” which was about weight loss drugs. A lot of people are upset that she's tal

If you're interested in broad exposure to the Healthcare - Pharma segment of the equity market, look no further than the VanEck Pharmaceutical ETF (PPH), a passively managed exchange traded fund launc

Top ETFs to buy offer a smart solution for those looking to diversify their portfolios without the hassle. In the investment realm, diversification remains a key aspect of a sound investment strategy,

Healthcare stocks started the year off very strongly as investors cheered the sector's advances. Among the sector's catalysts have been continued, strong enthusiasm for a new class of weight-loss drug

Investors seeking momentum may have iShares VanEck Pharmaceutical ETF PPH on radar now. The fund recently hit a new 52-week high.

The fourth-quarter results of the healthcare sector have been unimpressive, with earnings of companies that have reported so far down 17.7% despite 7% revenue growth. However, many industry bigwigs re

Pharmaceuticals underperformed the S&P 500 in 2023 but have been outperforming the broader market in 2024. The PPH fund offers exposure to pharmaceutical stocks and has outperformed its peers in terms

The healthcare sector presents a unique investment opportunity in 2024 due to attractive valuation and uncorrelated/robust cashflow of healthcare. Biopharma companies have pricing power and ability to